Protocols of Standard of Care for Adult Patients with Primary Antibody Deficiencies Will Improve Timing of Diagnosis, Survival, and Quality of Life
Guidelines and Protocols of Care for Patients with PAD
-
Katarzyna Napiórkowska-Baran
,
Ewa Więsik-Szewczyk
,
Marcin Ziętkiewicz
,
Aleksandra Matyja-Bednarczyk
,
Sylwia Kołtan
,
Natalia Bąkowska-Kocik
,
Tomasz Rosada
,
Karolina Baranowska
,
Ewa Alska
,
Marta Tykwińska
,
Ewa Szynkiewicz
,
Robert Zacniewski
,
Zbigniew Bartuzi
Abstract
The majority of primary immunodeficiencies (PIDs) are antibody deficiencies (PADs), and not all of them are rare diseases; As an example, Caucasian individuals suffer from selective IgA deficiency at a frequency of 1:500.
In addition to infections, symptomatic patients with PAD are more likely to develop neoplastic, autoimmune, and allergic diseases. In the event that PAD is neglected or delayed for more than ten years, complications develop, eventually resulting in death. No studies have been conducted to devise and report detailed ready-to-use protocols for managing PAD to date.
This study aimed to propose protocols and guidelines for the adult PAD patients’ standard care. Preparing the protocol, we considered the frequency and type of laboratory tests, imaging, endoscopic examinations, specialist consultations, and standardized recommendations for further care in the place of residence.
As a result of the proposed monitoring scheme, patients can be provided with complete care in terms of their underlying conditions and comorbidities, as well as early detection of complications. This protocol will serve as a guide for physicians dealing with these patients and enable comparisons of patient groups across a variety of treatment centers, even far away from each other. A national consultant in the field of clinical immunology verified the protocol mainly developed by Polish experts from reference immunology centres for adults.
1. Patel NC. Individualized immunoglobulin treatment in pediatric patients with primary humoral immunodeficiency disease. Pediatr Allergy Immunol. 2018;29(6):583-8.
2. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717-732.
3. Joshi AY, Iyer VN, Hagan JB, St Saver JL, Boyce TG. Incidence and temporal trends of a primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16-22.
4. Lehman H, Hernandez-Trujillo V, Ballow M. Diagnosing primary immunodeficiency: a practical approach for the non-immunologist. Curr Med Res Opin. 2015:31(4):697-706.
5. Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. ESID Registry Working Party. The European Internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009;157(suppl 1):3-11.
6. Abolhassani H, Kiaee F, Tavakol M, Chavoshzadeh Z, Mahdaviani SA, Momen T, et al. Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis. J Clin Immunol. 2018;38(7):816-832.
7. Gathmann B, Mahlaoui N,Oksenhendler E, Warnatz K, Schulze I, Kindle G, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-6.
8. Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58 (Suppl 3):3056-64.
9. Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol. 2017;14(1):7-18
10. Linares NA, Bouchard M, Gutiérrez NS, Colmenares M, Cantor-Garcia A, Gabaldon-Figueira JC, et al. Immunological features in pediatric patients with recurrent and severe infection: Identification of Primary Immunodeficiency Diseases in Merida, Venezuela. Allergol Immunopathol (Madr). 2019;47(5):437-48.
11. Mahlaoui N, Jais JP, Brosselin P, Mignot C, Beaurain B, Brito C, Costes L, Courteille V, De Vergnes N, Alcaïs A, Fischer A; CEREDIH Prevalence Study Collaborators. Prevalence of primary immunodeficiencies in France is underestimated. J Allergy Clin Immunol. 2017;140(6):1731-1733.
12. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717-32.
13. Pilania RK, Chaudhary H, Jindal AK, Rawat A, Singh S. Current status and prospects of primary immunodeficiency diseases in Asia. Genes Dis. 2019;7(1):3-11.
14. Singh A, Jindal AK, Joshi V, Anjani G, Rawat A. An updated review on phenocopies of primary immunodeficiency diseases. Genes Dis. 2019;7(1):12-25.
15. Coopmans EC, Chunharojrith P, Neggers SJCMM, van der Ent MW, Swagemakers SMA, Hollink IH, et al. Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies. Front Immunol. 2019;10(4):2079.
16. Więsik-Szewczyk E, Ziętkiewicz M, Matyja-Bednarczyk A, Napiórkowska-Baran K, Suchanek H, Jahnz-Różyk K. The first Polish cohort of adult patients with common variable immunodeficiency from 4 specialized centers: do we provide standards of care? Pol Arch Intern Med. 2018;128(9):563-6.
17. Çalişkaner AZ, Reisli İ, Arslan Ş, Uçar R, Ataseven H, Selçuk NY. Common variable immunodeficiency in adults requires reserved protocols for long-term follow-up. Turk J Med. Sci. 2016;46(2):430-6.
18. Villavicencio MF, Pedroza LA. Diagnosis of primary immunodeficiency diseases in the developing world: the need for education and networking with the developed world. Curr Opin Pediatr. 2019;31(6):835-42.
19. Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo García-Morato M, et al. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. J Allergy Clin Immunol Pract. 2020;8(10):3342-7.
20. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.
21. Perez EE, Ballow M. Diagnosis and management of Specific Antibody Deficiency. Immunol Allergy Clin North Am. 2020;40(3):499-510.
22. Maglione PJ. Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management. Immunol Allergy Clin North Am. 2020;40(3):437-59.
23. Mokhtari M, Shakeri A, Mirminachi B, Abolhassani H, Yazdani R, Grimbacher B, et al. Important Factors Influencing Severity of Common Variable Immunodeficiency. Arch Iran Med. 2016;19(8):544-50.
24. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of Nutrient Modulation of the Immune Response. J Allergy Clin Immunol. 115(6), 1119-28
25. Chandra RK. Nutrition and the Immune System From Birth to Old Age. Eur J Clin Nutr. 2002; (56 Suppl 3):S73-6.
26. Chandra RK. Nutrient Regulation of Immune Functions . Forum Nutr. 2003;56:147-8.
27. Iliakis D, Kressig RW. The relationship between malnutrition and immune. Ther Umsch. 2014;71(1):55-61.
28. Blackwell J. Identification, Evaluation, and Treatment of Overweight and Obese Adults. Am Acad Nurse Pract. 2002;14(5):196-8.
29. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22 (7 Suppl):176-85.
30. Williams EP, Mesidor M, Winters K, Dubbert P. Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem Curr Obes Rep Sep. 2015;4(3):363-70.
31. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive Summary: Guidelines (2013) for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society Published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a Systematic Review From the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 22 Suppl 2, S5-39.
32. Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353-63.
33. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate Dehydrogenase A in Cancer: A Promising Target for Diagnosis and Therapy. IUBMB Life. 2013;65(11):904-10.
34. Gallo M, SapioL, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic Dehydrogenase and Cancer: An Overview. Front Biosci (Landmark Ed). 2015;20(2):1234-49.
35. Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, et al. Serum Uric Acid Increases Risk of Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. Mediators Inflamm. 2015;2015:764250.
36. Higdon ML, Atkinson CJ, Lawrence KV. Oncologic Emergencies: Recognition and Initial Management. Am Fam Physician. 2018;97(11):741-8.
37. Kornum JB, Farkas DK, Sværke C, Severinsen MT, Thomsen RW, Sørensen HT. Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate. Cancer Epidemiol Biomarkers Prev. 2019;28(1):225-32.
38. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41
39. Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7.
40. Karr S. Epidemiology and management of hyperlipidemia. Am J ManagCare. 2017;23(9 Suppl):S139-S148.
41. Agabiti Rosei E, Salvetti M. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev. 2016;23(3):217-30.
42. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease: is it safe and effective? Eur Heart J. 2015;36(43):2988-95.
43. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med. 1991;115(8):623-38.
44. Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY). 2019;44(4):1575-1600.
45. Reiter MJ, Costello JE, Schwope RB, Lisanti CJ, Osswald MB. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. J Comput Assist Tomogr. 2015;39(6):825-34.
46. Amiri FS. Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers. Ren Fail. 2016;38(4):530-44.
47. Reisi M, Azizi G, Kiaee F, Masiha F, Shirzadi R, Momen T, et al. Evaluation of pulmonary complications in patients with primary immunodeficiency disorders. Eur Ann Allergy Clin Immunol. 2017;49(3):122-8.
48. Weinberger T, Fuleihan R, Cunningham-Rundles C, Maglione PJ. Factors Beyond Lack of Antibody Govern Pulmonary Complications in Primary Antibody Deficiency. J Clin Immunol. 2019;39(4):440-7.
49. Schussler E, Beasley MB, Maglione PJ. Lung Disease in Primary Antibody Deficiencies .J Allergy Clin Immunol Pract. 2016;4(6):1039-52.
50. Cinetto F, Scarpa R, Rattazzi M, Agostini C. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018;27(149):180019.
51. Kobrynski LJ. Noninfectious Complications of Common Variable Immune Deficiency. Allergy Asthma Proc. 2019;40(2):129-32
52. Pikkarainen S, Martelius T, Ristimäki A, Siitonen S, Seppänen MRJ, Färkkilä M. A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. Am J Gastroenterol. 2019;114(4):648-55
53. Agarwal S, Cunningham-Rundles C. Gastrointestinal Manifestations and Complications of Primary Immunodeficiency Disorders. Immunol Allergy Clin North Am. 2019;39(1):81-94.
54. Leone P, Vacca A, Dammacco F, Racanelli V. Common Variable Immunodeficiency and Gastric Malignancies. Int J Mol Sci. 2018;19(2):451.
55. KayanOcakoglu B, Karaca NE, Ocakoglu FT, Erermis S. Psychological burden of pediatric primary immunodeficiency. Pediatr Int. 2018;60(10):911-7.
56. Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(7):844-52.
57. Mozaffari H, Pourpak Z, Pourseyed S, Moin M, Farhoodi A, Aghamohammadi A, et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol. 2006;5(1):23-7.
58. Zebracki K, Palermo TM, Hostoffer R, Duff K, Drotar D. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93(6):557-61.
59. Kuburovic NB, Pasic S, Susic G, Stevanovic D, Kuburovic V, Zdravkovic S, JanicijevicPetrovic M, et al. T Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323-30.
60. Abolhassani H, Aghamohammadi A, Pourjabbar S, SalehiSadaghiani M, Nikayin S, Rabiee A, et al. Psychiatric aspects of primary immunodeficiency diseases: the parental study. Iran J Allergy Asthma Immunol. 2013;12(2):176-81.
61. Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Yonsei. Health related quality of life in common variable immunodeficiency. Med J. 2012;53(3):603-10.
62. Sigstad HM, Stray-Pedersen A, Frøland SS. Coping, quality of life, and hope in adults with primary antibody deficiencies. HealthQual Life Outcomes. 2005;3:31.
63. Tabolli S, Giannantoni P, Pulvirenti F, La Marra F, Granata G, Milito C, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:605
64. Rider NL, Kutac C, Hajjar J, Scalchunes C, Seeborg FO, Boyle M, et al. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment. J ClinImmunol. 2017;37(5):461-75.
65. Andersen JB, Midttun K, Feragen KJB. Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL). J Patient Rep Outcomes. 2019;3(1):15.
66. Quinti I, Pulvirenti F, Giannantoni P, Hajjar J, Canter DL, Milito C, et al. Development and Initial Validation of a Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency: The CVID_QoL Questionnaire. J Allergy Clin Immunol Pract. 2016;4(6):1169-79.e4.
67. Heath J, Lehman E, Saunders EF, Craig T. Anxiety and depression in adults with primary immunodeficiency: How much do these patients experience and how much do they attribute to their primary immunodeficiency? Allergy Asthma Proc. 2016;37(5):409-15.
68. Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda. J Clin Immunol. 2016;36(2):123-33.
69. Bethune C, Egner W, Garcez T, Huissoon A, Jolles S, Karim Y, et al. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders. Clin Exp Immunol. 2019;196(3):328-35
70. Janssen LMA, Bassett P, Macken T, van Esch J, Pruijt H, Knoops A, et al. Mild Hypogammaglobulinemia Can Be a Serious Condition. Front Immunol. 2018;9:2384
71. Läubli J, Dobrota R, Maurer B, Jordan S, Misselwitz B, Fox M, et al. Impaired micronutrients and prealbumin in patients with established and very early systemic sclerosis. Clin Exp Rheumatol. 2020;125(3):120-6.
72. Sanz-Cuesta T, Escortell-Mayor E, Cura-Gonzalez I, Martin-Fernandez J, Riesgo-Fuertes R, Garrido-Elustondo S, et al Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12). BMJ Open 2020;10(8):e033687
73. Jolles S, Sánchez-Ramón S, Quinti I, Soler-Palacín P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190(2):226-34.
74. Cinetto F, Scarpa R, Pulvirenti F, Quinti I, Agostini C, Milito C. Appropriate lung management in patients with primary antibody deficiencies. Expert Rev Respir Med. 2019;13(9):823-38.
75. Grzesk E, Dabrowska A, Urbanczyk A, Ewertowska M, Tejza B, Grzesk G, et al. Common variable immunodeficiency disorders – diseases with many faces. Pediatr Pol. 2018;93(2):186-91
76. Shin JH, Baek JH, Chung J. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2016;17(3):370-95.
77. Xue E, Zheng M, Zhang S, Huang L, Qian Q, Huang Y. Ultrasonography-Based Classification and Reporting System for the Malignant Risk of Thyroid Nodules. J Nippon Med Sch. 2017;84(3):118-24.
78. Oeffinger KC, Fontham ET, Etzioni R. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314(15):1599-614.
79. Barberato SH, Romano MMD, Beck ALS. Position Statement on Indications of Echocardiography in Adults - 2019. Arq Bras Cardiol. 2019;113(1):135-81. Published 2019 Aug 8.
80. Banks M, Graham D, Jansen M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-75.
81. Tinmouth J, Vella ET, Baxter NN, et al. Colorectal Cancer Screening in Average Risk Populations: Evidence Summary. Can J Gastroenterol Hepatol. 2016;2016:2878149.
82. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1465-96.e17.
83. Lamb CA, Kennedy NA, Raine T. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106.
84. Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol. 2016;37(6):386-98.
85. Gaffney DK, Hashibe M, Kepka D, Maurer KA, Werner TL. Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol. 2018;151(3):547-54.
86. Miller JW, Hanson V, Johnson GD, Royalty JE, Richardson LC. From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer. 2014;16(16):2549-56.
87. Sowers KL, Litwin BA, Lee ACW, Galantino MLA. Exercise Perception and Behaviors in Individuals Living with Primary Immunodeficiency Disease. J Clin Immunol. 2018;38(2):174-84.
88. Ziętkiewicz M, Więsik-Szewczyk E, Matyja-Bednarczyk A, Napiórkowska-Baran K, Zdrojewski Z, Jahnz-Różyk K. Shorter Diagnostic Delay in Polish Adult Patients With Common Variable Immunodeficiency and Symptom Onset After 1999. Front Immunol. 2020;11:982.
89. Singh S, Zhao X, Zhang H. Primary Immune Deficiencies - A rapidly emerging area of basic and clinical research. Genes Dis. 2020;7(1):1-2.
90. Bonilla FA, Barlan I, Chapel H. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
2. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717-732.
3. Joshi AY, Iyer VN, Hagan JB, St Saver JL, Boyce TG. Incidence and temporal trends of a primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16-22.
4. Lehman H, Hernandez-Trujillo V, Ballow M. Diagnosing primary immunodeficiency: a practical approach for the non-immunologist. Curr Med Res Opin. 2015:31(4):697-706.
5. Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. ESID Registry Working Party. The European Internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009;157(suppl 1):3-11.
6. Abolhassani H, Kiaee F, Tavakol M, Chavoshzadeh Z, Mahdaviani SA, Momen T, et al. Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis. J Clin Immunol. 2018;38(7):816-832.
7. Gathmann B, Mahlaoui N,Oksenhendler E, Warnatz K, Schulze I, Kindle G, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-6.
8. Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58 (Suppl 3):3056-64.
9. Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol. 2017;14(1):7-18
10. Linares NA, Bouchard M, Gutiérrez NS, Colmenares M, Cantor-Garcia A, Gabaldon-Figueira JC, et al. Immunological features in pediatric patients with recurrent and severe infection: Identification of Primary Immunodeficiency Diseases in Merida, Venezuela. Allergol Immunopathol (Madr). 2019;47(5):437-48.
11. Mahlaoui N, Jais JP, Brosselin P, Mignot C, Beaurain B, Brito C, Costes L, Courteille V, De Vergnes N, Alcaïs A, Fischer A; CEREDIH Prevalence Study Collaborators. Prevalence of primary immunodeficiencies in France is underestimated. J Allergy Clin Immunol. 2017;140(6):1731-1733.
12. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717-32.
13. Pilania RK, Chaudhary H, Jindal AK, Rawat A, Singh S. Current status and prospects of primary immunodeficiency diseases in Asia. Genes Dis. 2019;7(1):3-11.
14. Singh A, Jindal AK, Joshi V, Anjani G, Rawat A. An updated review on phenocopies of primary immunodeficiency diseases. Genes Dis. 2019;7(1):12-25.
15. Coopmans EC, Chunharojrith P, Neggers SJCMM, van der Ent MW, Swagemakers SMA, Hollink IH, et al. Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies. Front Immunol. 2019;10(4):2079.
16. Więsik-Szewczyk E, Ziętkiewicz M, Matyja-Bednarczyk A, Napiórkowska-Baran K, Suchanek H, Jahnz-Różyk K. The first Polish cohort of adult patients with common variable immunodeficiency from 4 specialized centers: do we provide standards of care? Pol Arch Intern Med. 2018;128(9):563-6.
17. Çalişkaner AZ, Reisli İ, Arslan Ş, Uçar R, Ataseven H, Selçuk NY. Common variable immunodeficiency in adults requires reserved protocols for long-term follow-up. Turk J Med. Sci. 2016;46(2):430-6.
18. Villavicencio MF, Pedroza LA. Diagnosis of primary immunodeficiency diseases in the developing world: the need for education and networking with the developed world. Curr Opin Pediatr. 2019;31(6):835-42.
19. Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo García-Morato M, et al. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. J Allergy Clin Immunol Pract. 2020;8(10):3342-7.
20. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.
21. Perez EE, Ballow M. Diagnosis and management of Specific Antibody Deficiency. Immunol Allergy Clin North Am. 2020;40(3):499-510.
22. Maglione PJ. Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management. Immunol Allergy Clin North Am. 2020;40(3):437-59.
23. Mokhtari M, Shakeri A, Mirminachi B, Abolhassani H, Yazdani R, Grimbacher B, et al. Important Factors Influencing Severity of Common Variable Immunodeficiency. Arch Iran Med. 2016;19(8):544-50.
24. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of Nutrient Modulation of the Immune Response. J Allergy Clin Immunol. 115(6), 1119-28
25. Chandra RK. Nutrition and the Immune System From Birth to Old Age. Eur J Clin Nutr. 2002; (56 Suppl 3):S73-6.
26. Chandra RK. Nutrient Regulation of Immune Functions . Forum Nutr. 2003;56:147-8.
27. Iliakis D, Kressig RW. The relationship between malnutrition and immune. Ther Umsch. 2014;71(1):55-61.
28. Blackwell J. Identification, Evaluation, and Treatment of Overweight and Obese Adults. Am Acad Nurse Pract. 2002;14(5):196-8.
29. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22 (7 Suppl):176-85.
30. Williams EP, Mesidor M, Winters K, Dubbert P. Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem Curr Obes Rep Sep. 2015;4(3):363-70.
31. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive Summary: Guidelines (2013) for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society Published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a Systematic Review From the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 22 Suppl 2, S5-39.
32. Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353-63.
33. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate Dehydrogenase A in Cancer: A Promising Target for Diagnosis and Therapy. IUBMB Life. 2013;65(11):904-10.
34. Gallo M, SapioL, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic Dehydrogenase and Cancer: An Overview. Front Biosci (Landmark Ed). 2015;20(2):1234-49.
35. Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, et al. Serum Uric Acid Increases Risk of Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. Mediators Inflamm. 2015;2015:764250.
36. Higdon ML, Atkinson CJ, Lawrence KV. Oncologic Emergencies: Recognition and Initial Management. Am Fam Physician. 2018;97(11):741-8.
37. Kornum JB, Farkas DK, Sværke C, Severinsen MT, Thomsen RW, Sørensen HT. Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate. Cancer Epidemiol Biomarkers Prev. 2019;28(1):225-32.
38. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41
39. Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7.
40. Karr S. Epidemiology and management of hyperlipidemia. Am J ManagCare. 2017;23(9 Suppl):S139-S148.
41. Agabiti Rosei E, Salvetti M. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev. 2016;23(3):217-30.
42. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease: is it safe and effective? Eur Heart J. 2015;36(43):2988-95.
43. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med. 1991;115(8):623-38.
44. Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY). 2019;44(4):1575-1600.
45. Reiter MJ, Costello JE, Schwope RB, Lisanti CJ, Osswald MB. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. J Comput Assist Tomogr. 2015;39(6):825-34.
46. Amiri FS. Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers. Ren Fail. 2016;38(4):530-44.
47. Reisi M, Azizi G, Kiaee F, Masiha F, Shirzadi R, Momen T, et al. Evaluation of pulmonary complications in patients with primary immunodeficiency disorders. Eur Ann Allergy Clin Immunol. 2017;49(3):122-8.
48. Weinberger T, Fuleihan R, Cunningham-Rundles C, Maglione PJ. Factors Beyond Lack of Antibody Govern Pulmonary Complications in Primary Antibody Deficiency. J Clin Immunol. 2019;39(4):440-7.
49. Schussler E, Beasley MB, Maglione PJ. Lung Disease in Primary Antibody Deficiencies .J Allergy Clin Immunol Pract. 2016;4(6):1039-52.
50. Cinetto F, Scarpa R, Rattazzi M, Agostini C. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018;27(149):180019.
51. Kobrynski LJ. Noninfectious Complications of Common Variable Immune Deficiency. Allergy Asthma Proc. 2019;40(2):129-32
52. Pikkarainen S, Martelius T, Ristimäki A, Siitonen S, Seppänen MRJ, Färkkilä M. A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. Am J Gastroenterol. 2019;114(4):648-55
53. Agarwal S, Cunningham-Rundles C. Gastrointestinal Manifestations and Complications of Primary Immunodeficiency Disorders. Immunol Allergy Clin North Am. 2019;39(1):81-94.
54. Leone P, Vacca A, Dammacco F, Racanelli V. Common Variable Immunodeficiency and Gastric Malignancies. Int J Mol Sci. 2018;19(2):451.
55. KayanOcakoglu B, Karaca NE, Ocakoglu FT, Erermis S. Psychological burden of pediatric primary immunodeficiency. Pediatr Int. 2018;60(10):911-7.
56. Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(7):844-52.
57. Mozaffari H, Pourpak Z, Pourseyed S, Moin M, Farhoodi A, Aghamohammadi A, et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol. 2006;5(1):23-7.
58. Zebracki K, Palermo TM, Hostoffer R, Duff K, Drotar D. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93(6):557-61.
59. Kuburovic NB, Pasic S, Susic G, Stevanovic D, Kuburovic V, Zdravkovic S, JanicijevicPetrovic M, et al. T Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323-30.
60. Abolhassani H, Aghamohammadi A, Pourjabbar S, SalehiSadaghiani M, Nikayin S, Rabiee A, et al. Psychiatric aspects of primary immunodeficiency diseases: the parental study. Iran J Allergy Asthma Immunol. 2013;12(2):176-81.
61. Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Yonsei. Health related quality of life in common variable immunodeficiency. Med J. 2012;53(3):603-10.
62. Sigstad HM, Stray-Pedersen A, Frøland SS. Coping, quality of life, and hope in adults with primary antibody deficiencies. HealthQual Life Outcomes. 2005;3:31.
63. Tabolli S, Giannantoni P, Pulvirenti F, La Marra F, Granata G, Milito C, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:605
64. Rider NL, Kutac C, Hajjar J, Scalchunes C, Seeborg FO, Boyle M, et al. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment. J ClinImmunol. 2017;37(5):461-75.
65. Andersen JB, Midttun K, Feragen KJB. Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL). J Patient Rep Outcomes. 2019;3(1):15.
66. Quinti I, Pulvirenti F, Giannantoni P, Hajjar J, Canter DL, Milito C, et al. Development and Initial Validation of a Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency: The CVID_QoL Questionnaire. J Allergy Clin Immunol Pract. 2016;4(6):1169-79.e4.
67. Heath J, Lehman E, Saunders EF, Craig T. Anxiety and depression in adults with primary immunodeficiency: How much do these patients experience and how much do they attribute to their primary immunodeficiency? Allergy Asthma Proc. 2016;37(5):409-15.
68. Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda. J Clin Immunol. 2016;36(2):123-33.
69. Bethune C, Egner W, Garcez T, Huissoon A, Jolles S, Karim Y, et al. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders. Clin Exp Immunol. 2019;196(3):328-35
70. Janssen LMA, Bassett P, Macken T, van Esch J, Pruijt H, Knoops A, et al. Mild Hypogammaglobulinemia Can Be a Serious Condition. Front Immunol. 2018;9:2384
71. Läubli J, Dobrota R, Maurer B, Jordan S, Misselwitz B, Fox M, et al. Impaired micronutrients and prealbumin in patients with established and very early systemic sclerosis. Clin Exp Rheumatol. 2020;125(3):120-6.
72. Sanz-Cuesta T, Escortell-Mayor E, Cura-Gonzalez I, Martin-Fernandez J, Riesgo-Fuertes R, Garrido-Elustondo S, et al Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12). BMJ Open 2020;10(8):e033687
73. Jolles S, Sánchez-Ramón S, Quinti I, Soler-Palacín P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190(2):226-34.
74. Cinetto F, Scarpa R, Pulvirenti F, Quinti I, Agostini C, Milito C. Appropriate lung management in patients with primary antibody deficiencies. Expert Rev Respir Med. 2019;13(9):823-38.
75. Grzesk E, Dabrowska A, Urbanczyk A, Ewertowska M, Tejza B, Grzesk G, et al. Common variable immunodeficiency disorders – diseases with many faces. Pediatr Pol. 2018;93(2):186-91
76. Shin JH, Baek JH, Chung J. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2016;17(3):370-95.
77. Xue E, Zheng M, Zhang S, Huang L, Qian Q, Huang Y. Ultrasonography-Based Classification and Reporting System for the Malignant Risk of Thyroid Nodules. J Nippon Med Sch. 2017;84(3):118-24.
78. Oeffinger KC, Fontham ET, Etzioni R. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314(15):1599-614.
79. Barberato SH, Romano MMD, Beck ALS. Position Statement on Indications of Echocardiography in Adults - 2019. Arq Bras Cardiol. 2019;113(1):135-81. Published 2019 Aug 8.
80. Banks M, Graham D, Jansen M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-75.
81. Tinmouth J, Vella ET, Baxter NN, et al. Colorectal Cancer Screening in Average Risk Populations: Evidence Summary. Can J Gastroenterol Hepatol. 2016;2016:2878149.
82. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1465-96.e17.
83. Lamb CA, Kennedy NA, Raine T. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106.
84. Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol. 2016;37(6):386-98.
85. Gaffney DK, Hashibe M, Kepka D, Maurer KA, Werner TL. Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol. 2018;151(3):547-54.
86. Miller JW, Hanson V, Johnson GD, Royalty JE, Richardson LC. From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer. 2014;16(16):2549-56.
87. Sowers KL, Litwin BA, Lee ACW, Galantino MLA. Exercise Perception and Behaviors in Individuals Living with Primary Immunodeficiency Disease. J Clin Immunol. 2018;38(2):174-84.
88. Ziętkiewicz M, Więsik-Szewczyk E, Matyja-Bednarczyk A, Napiórkowska-Baran K, Zdrojewski Z, Jahnz-Różyk K. Shorter Diagnostic Delay in Polish Adult Patients With Common Variable Immunodeficiency and Symptom Onset After 1999. Front Immunol. 2020;11:982.
89. Singh S, Zhao X, Zhang H. Primary Immune Deficiencies - A rapidly emerging area of basic and clinical research. Genes Dis. 2020;7(1):1-2.
90. Bonilla FA, Barlan I, Chapel H. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
| Files | ||
| Issue | Vol 21 No 4 (2022) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v21i4.10285 | |
| Keywords | ||
| Adult Clinical protocols Guideline adherence Primary immunodeficiency diseases Standard of care | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Napiórkowska-Baran K, Więsik-Szewczyk E, Ziętkiewicz M, Matyja-Bednarczyk A, Kołtan S, Bąkowska-Kocik N, Rosada T, Baranowska K, Alska E, Tykwińska M, Szynkiewicz E, Zacniewski R, Bartuzi Z. Protocols of Standard of Care for Adult Patients with Primary Antibody Deficiencies Will Improve Timing of Diagnosis, Survival, and Quality of Life. Iran J Allergy Asthma Immunol. 2022;21(4):374-387.
